BlueWind Medical has received FDA 510(k) clearance for Revi Extend, a next-generation implant designed to increase treatment durability for urgency urinary incontinence (UUI) from 10 to 15 years.

The latest version of the company’s implantable tibial neuromodulation (ITNM) system is intended to reduce the long-term treatment burden for patients living with the chronic condition while expanding the lifespan of the minimally invasive therapy. BlueWind said it plans a limited US launch of Revi Extend during the fourth quarter of 2026.

FDA clearance extends implant lifespan

The newly cleared implant builds on the existing Revi system, which is implanted near the ankle during an outpatient procedure performed under local anaesthesia. The device stimulates the posterior tibial nerve using an external wearable controller to help manage symptoms of urgency urinary incontinence.

By extending the implant’s lifespan from 10 years to 15 years, BlueWind aims to reduce the likelihood of replacement procedures while allowing patients to benefit from therapy over a longer period.

Kerry Nelson, chief executive officer of BlueWind Medical, said: “FDA clearance of our next-generation implant reflects our continued commitment to meaningful innovation for patients and physicians. Extending implant durability coupled with our remotely enabled software advancements allows patients to receive the latest therapy innovations for fifteen years into the future.”

Urgency urinary incontinence affects millions of people worldwide and is characterised by a sudden, difficult-to-control need to urinate. Neuromodulation therapies are increasingly used when conservative treatments or medication fail to provide adequate symptom control.

Long-term clinical data support the technology

The company said the next-generation implant builds on previously published clinical evidence demonstrating sustained symptom improvement and patient satisfaction with the Revi system.

According to three-year data from the pivotal Oasis study, 79% of patients achieved at least a 50% reduction in urgency urinary incontinence episodes, while 63% experienced a reduction of at least 75%. The study also reported that 95% of patients remained satisfied with the therapy after three years, with no device- or procedure-related serious adverse events reported during follow-up.

Unlike some alternative neuromodulation therapies, the Revi system is implanted during a single minimally invasive outpatient procedure and does not require an initial trial phase.

Growing role for neuromodulation in bladder disorders

The latest clearance reflects continued development in implantable neuromodulation technologies designed to provide longer-lasting treatment options for chronic bladder disorders.

BlueWind said Revi Extend has been designed to give patients greater control over their therapy while reducing long-term maintenance requirements. The company also believes the longer implant lifespan could offer healthcare providers an additional treatment option for patients seeking durable symptom relief without repeated surgical intervention.

The limited commercial launch planned later this year will provide the first opportunity for clinicians to begin using the longer-lasting implant in routine clinical practice.